Negev Labs
- Biotech or pharma, therapeutic R&D
Negev Labs: Scalable Neuropsychiatric Therapies Backed by Human Data
Negev Labs is advancing two differentiated drug candidates that target major unmet needs in neuropsychiatry. These small-molecule 5-HT2A agonists are non-hallucinogenic and supported by compelling human safety and efficacy data—offering pharma-compatible profiles suitable for scalable development.
- Lead Asset – Apathy in Parkinson’s Disease: A proprietary analog of a rediscovered compound originally developed and tested by a major pharmaceutical company in the 1970s in over 500 patients. Clinical data demonstrated statistically significant improvements in Parkinson's disease patients. A Phase Ib study in Parkinson’s is planned for 1H 2025.
- Second Program – Impulsivity and Aggression (ADHD / Orphan Neurobehavioral): A novel serotonergic compound with extensive anecdotal human use suggesting efficacy in reducing impulsivity and aggression without stimulant-like side effects. IND-enabling studies are targeted for 2026.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}